Clinical trial
Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium…
NCT00421590 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00421590 |
|---|---|
| Title | Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide). |
| Official title | A Randomized, Partially Blind, Placebo Controlled, Crossover, Single Oral Dose Study to Assess the Effect of Concomitant Antacid (Calcium Carbonate / Magnesium Hydroxide) on the Pharmacokinetics and Pharmacodynamics of SMC021 (0.8 mg Salmon Calcitonin/200 mg 5-CNAC) in Healthy Postmenopausal Women |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Health Postmenopausal Women |
| Intervention type | Drug |
| Interventions | SMC021 |
| Enrollment | 38 |
| Start date | Oct 1, 2006 |
| First posted | Jan 12, 2007 |
| Last update posted | Jun 22, 2007 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: